Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96.

Lancet Reg Health West Pac · 2023 · PMC10398592 · PMID 37547039

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

14 The median change of HIV-1 RNA log 10 from baseline to week 48 was −2.90 (95% CI: −2.91 to −2.75) in the ANV group and −2.80 (−2.89 to −2.74) in the EFV group, but the apparent difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.